News
![Boehringer Ingelheim, Biberach, Germany, February 2007](https://pharmaphorum.com/wp-content/uploads/2016/05/BI-sign.jpg)
Boehringer bags first approval for rare skin disease drug
German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP)